Nature - 15.08.2019

2

nature research | reporting summary

October 2018

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size No sample size calculation was done. Sample size was chosen based on the consistency and magnitude of measured

differences between groups.

Data exclusions No data were excluded from analysis.

Replication All attempts replicated similar results. We have repeated each experiment in the manuscript at least twice to ensure consistent results. We

have also provided detailed protocols in the methods section that will help replicate these results for other researchers.

Randomization No randomization was necessary as various infection samples were recorded and analyzed by a computer software for extracting the

significant differences.

Blinding Blinding was not relevant for the experiments done as various infection samples were imaged and analyzed by a computer software for

extracting the significant differences.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,

system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a Involved in the study

Antibodies

Eukaryotic cell lines

Palaeontology

Animals and other organisms

Human research participants

Clinical data

Methods

n/a Involved in the study

ChIP-seq

Flow cytometry

MRI-based neuroimaging

Antibodies

Antibodies used anti-Polyglutamylation Modification (Cat# GT335, Lot#A23941207, Provider:Adipogen technology, 1μg of antibody was used for

immunoprecipitation (IP) of 100μg of lysate)

Ubiquitin (Cat# 3936S, Lot#14, Provider: Cell signaling Technology, Dilution: 1:1000)

Ubiquitin Ubi-1 (Cat# ab7254, Lot#GR3174867-10, Provider: Abcam, Dilution: 1:5000)

GFP (B-2) (Cat # sc-9996, Lot# K2217, provider: Santa Cruz Biotechnology, )

Anti-tubulin (cat #:2128S, Lot#5, Provider: Cell signaling Technology, Dilution: 1:5000)

Anti-HA (cat #:sc-7392 Lot#L1018, Provider:Santa Cruz Biotechnology, Dilution: 1:1000)

Anti-CaM ( Cat #: 4830S, Lot# 3, Provider: Cell Signaling Technology, Dilution: 1:2000)

Anti-GST ( Cat #: 2625S, Lot# 8, Provider: Cell Signaling Technology, Dilution: 1:2000)

GFP trap beads (Cat #: gta-100 Lot# 90312001A, Provider: ChromoTek, beads were used for IP according to manufacturer's

recommendation)

Validation anti-Polyglutamylation Modification, mAb (GT335), validation statement from the manufacturer: Recognizes the

posttranslational modification (poly)glutamylation on proteins. Reacts with polyglutamylated α- and β-tubulin. validation found

at provider's website: https://adipogen.com/ag-20b-0020-anti-polyglutamylation-modification-mab-gt335.html/

Ubiquitin from Cell Signaling Technology (Cat:3936S), validation statement from the manufacture: Ubiquitin (P4D1) Mouse mAb

detects ubiquitin, polyubiquitin and ubiquitinated proteins. This antibody may cross-react with recombinant NEDD8.

Species Reactivity:

All Species Expected, Validation found at provider's website: https://www.cellsignal.com/products/primary-antibodies/ubiquitin-

p4d1-mouse-mab/3936